Search This Blog

Friday, April 17, 2026

NYPD new approach to stopping rampant shoplifting already paying off

 No more five-finger discounts.

The NYPD is beating back shoplifting — taking repeat offenders out of commission to help bring retail theft down by 20% so far this year, police officials told The Post this week.

NYPD Chief of Department Michael LiPetri credited the so-far successful citywide crackdown in part to changes in state law pushed by Gov. Kathy Hochul that allowed authorities to more effectively go after serial crooks. 

“Throughout the city, we are closing – which means making an arrest – just a few years ago, it was 40%.Now it’s on 50% [of cases]. So every shoplifting complaint that we take, we’ve made arrests on half of them,” LiPetri told The Post.

The NYPD stepped up its game to fight rampant retail theft in 2023 — and it’s paying off.Helayne Seidman

“That has really been a total game changer when it comes to recidivism, and also the businesses have gotten so much better by reporting.”

He said the action from Albany in 2024 — which permitted authorities to combine the values of goods stolen from multiple stores to slap on heavier charges and seek bail — has been a “total game changer.”

“Just a couple of years ago, 20% of individuals who committed a shoplifting offense got arrested with a new felony within 30 days or less,” he explained.

Now, just 13% of repeat offenders get re-arrested for a new felony in that same timeframe, LiPetri said. 

“We’re not looking to arrest individuals who are down on their luck and just went into a store randomly and left. We’re looking fully for recidivism to be dealt with,” he said.

NYPD Chief of Department Michael LiPetri said cops are taking a bit out of retail theft in the Big Apple.Lev Radin/Shutterstock

But the department’s tactic is “multi-layered,” the chief noted. 

“It’s not just one strategy. We implemented multiple strategies” — including beefed up street patrols in shoplifting hotspots that have cut retail thefts by more than 40% when cops are walking the beat.

“The community, the cops and the courts are all working together, and that has resulted in these dramatic increases,” Tom Harris, president of the Times Square Alliance told The Post.

“I used to get calls every day, every second day. [Now], I can’t remember the last call I got complaining about something from retailers,” Harris said Monday. 

“That, to me, is the definition of success.”

The city has seen nearly 3,000 fewer reported shoplifting incidents in the first quarter of 2026, with double digit declines in every single borough compared to the same timeframe in 2025, according to NYPD data.

As of Wednesday, a total of 12,607 retail theft incidents were reported to the NYPD, meaning the city is on pace for fewer than 44,000 total this year — compared to the 52,696 retail theft reports tallied in 2025.

It comes after retail theft surged during the COVID-19 pandemic, jumping a massive 64% from 2019 to 2023.

The pandemic-era surge ravaged stores statewide, including in New York City — leading to $4.4 billion in losses during 2022 alone, when shoplifting complaints surged to 63,000, a 45% leap from the previous year.

During the city’s shoplifting peak, the department investigated 17,112 retail theft cases in the first quarter of 2022, meaning the numbers so far this year mark a 26% decline. 

“Our retail theft initiative really started back in 2023, where we took a look at things and we just were not getting prosecutions that we were looking for when it came to recidivism,” LiPetri said.

NYPD Commissioner Jessica Tisch said the department is doubling down on retail thefts in eeh five boroughs.Andrew Schwartz / SplashNews.com

But thanks to the reforms passed as part of the 2024 state budget, the NYPD and Big Apple district attorneys have been able to collaborate on a winning strategy.

Authorities have taken advantage of changes in the law that allow cops to aggregate shoplifting incidents, so that thieves who used to get a slap on the wrist for stealing less than $1,000 worth of merchandise — a misdemeanor — can have the totals added up from different heists and face more serious grand larceny charges.

Cops are also now keeping better track of individual suspects, and also working with prosecutors to issue trespassing notices so accused thieves are barred from stores such as CVS and Duane Reade — and face additional charges if they run afoul of the court orders.

Those strengthened policies, as well as other changes that provided beefed-up protections for retail workers who get assaulted by shoplifters, have been helping keep career criminals behind bars, cops said. 

For instance, a suspect with more than 200 busts on his rap sheet, Laron Mack, was released after a petit larceny bust in 2023 — because the charge doesn’t qualify for bail under the state’s controversial 2019 criminal justice reforms — despite allegedly pinching from the same Manhattan Duane Reade at least a half dozen times.

Cops pointed to another accused recidivist thief, Raeed Clark, 41 – who has 85 arrests under his belt, 40 of them over the past two years – who is now staring down a potential jail sentence, authorities said. 

Clark, who is homeless, allegedly assaulted a worker at the Herald Square H&M store on Oct. 5, 2025 before making off with $75 in merchandise, police said. 

He’d previously been issued a trespass affidavit for repeated entries to the store – and he was slapped with robbery and assault charges under the strengthened protections for retail workers, police said.  

Some of the success also comes from good old-fashioned policing, like having cops walk the streets during the holiday season.

“We saw a 41% reduction in retail thefts … during the holiday seasons by putting officers on foot in large commercial strips,” LiPetri said, noting the effort stretched across the boroughs.

Target areas included Fordham Road in The Bronx, Main Street in Flushing, Queens and a stretch of 125th Street in Harlem — neighborhoods plagued by thieves in the past, the chief said.

NYPD Commissioner Jessica Tisch praised the results of the new approach.

“From everyday items like toothpaste and deodorant locked behind cases to small businesses struggling to stay open, last year, we applied a data-driven precision approach, identifying patterns, concentrating resources at high-propensity locations, and shifting from pass-through enforcement to sustained investigations,” Tisch said in a statement.

“The result was a 14 percent reduction in 2025,” the commissioner said. “And this year, we have doubled down and retail theft is down 20 percent citywide in the first quarter compared to last year, with double-digit declines in all five boroughs.”

https://nypost.com/2026/04/17/us-news/nypds-new-approach-to-rampant-shoplifting-paying-dividends-cops/

AI in medicine: a scoping review of the risk of deskilling and loss of expertise among physicians

 1, Pierre-etienne.heudel@lyon.unicancer.fr ∙ 2, ∙ 2, ∙ 1, ∙ 1,3,

Highlights

AI can erode physicians’ expertise; performance may drop when AI is removed.
Automation bias drives errors: clinicians may accept wrong AI cues or flip decisions.
Workflow shifts (e.g. fewer cases, AI training) can reduce hands-on learning.
Deskilling affects technical and cognitive skills, plus ethics and interpretation.
Mitigate with AI literacy, hybrid training, competence monitoring, and safeguards.

Abstract

Background

Artificial intelligence (AI) systems are increasingly deployed in clinical practice, particularly in radiology, pathology, endoscopy, and decision support. While these tools improve efficiency and accuracy, concerns have arisen about deskilling—the erosion of physicians’ expertise due to reliance on automation.

Materials and methods

We conducted a narrative review of empirical studies, randomized trials, and theoretical analyses published up to August 2025. The focus was on quantitative evidence of decreased performance following AI exposure, automation bias, and structural changes in training environments. Sources included PubMed, Embase, and gray literature.

Results

Evidence of clinical deskilling, though scarce, is consistent across specialties. In a multicenter randomized trial in colonoscopy, the adenoma detection rate (ADR) dropped significantly from 28.4% to 22.4% when endoscopists reverted to non-AI procedures after repeated AI use, while ADR remained stable with AI assistance (25.3%). In radiology, a controlled study of 27 breast imaging radiologists showed that erroneous AI prompts increased false-positive recalls by up to 12%, even among experienced readers. In computational pathology, experimental web-based tasks revealed that over 30% of participants reversed correct initial diagnoses when exposed to incorrect AI suggestions under time constraints. Structural deskilling has been reported in cytology following the UK’s transition to human papillomavirus primary screening, leading to an 80%-85% reduction in case volumes and consolidation of laboratories from 45 to 8 centers, with major implications for training capacity. Across domains, analyses confirm the presence of automation bias and highlight risks of diminished independent diagnostic reasoning.

Conclusions

Although limited in number, empirical studies consistently demonstrate that AI can inadvertently impair physicians’ performance or reduce opportunities for skill maintenance. Quantitative evidence of decreased diagnostic accuracy, error propagation, and training erosion underscores the need for longitudinal monitoring, adaptive curricula, and regulatory frameworks to mitigate deskilling. Safeguarding clinical expertise should be considered a central component of AI safety and resilience in medicine.

Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals

 

The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.

The collective attention of the oncology R&D community is turning toward San Diego. Beginning Friday, the city will host an American Association for Cancer Research annual meeting featuring updates from Merck, Amgen, Revolution Medicines and more with the potential to reshape cancer care and the priorities of R&D teams.

As was the case last year, one of AACR 2026’s most closely watched clinical data drops belongs to Merck. The drugmaker and its collaborators will share preliminary results from the first-in-human study of MK-2010, the PD-1/VEGF bispecific antibody that Merck licensed from Shanghai-based LaNova Medicines for $588 million upfront in 2024.

Merck struck the deal after another PD-1/VEGF bispecific, Akeso and Summit Therapeutics’ ivonescimab, beat its blockbuster checkpoint inhibitor Keytruda in a head-to-head clinical trial. The MK-2010 readout will provide an early look at Merck’s chances of competing with ivonescimab, as well as Pfizer and partners BioNTech and Bristol Myers Squibb, in the race to deliver the next backbone oncology treatment.

Jia Luo, a medical oncologist at Dana-Farber Cancer Institute, is closely watching the RAS space. In an email to BioSpace, she listed updates on the “promising” allele-specific RAS inhibitors zoldonrasib and elisrasib in KRAS-mutated non-small cell lung cancer (NSCLC) among the presentations she’s looking forward to at AACR 2026.

Revolution Medicines—which already made the biggest splash of this week with its pancreatic cancer data—is sharing preliminary safety and clinical activity data on another asset, zoldonrasib, which targets the G12D mutation in KRAS-dependent cancers. The biotech reported a 61% objective response rate in a Phase 1 NSCLC trial last year, though that figure included unconfirmed responses. Merck reportedly engaged in talks early this year to acquire Revolution for about $30 billion.

Meanwhile, elisrasib is a KRAS G12C inhibitor in development at D3 Bio. At AACR 2025, the Chinese biotech reported Phase 2 data showing a 30% response rate in 20 NSCLC patients who progressed on other KRAS G12C drugs such as Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. This year’s update will include Phase 1/2 monotherapy data on elisrasib in advanced NSCLC patients previously treated with or without a KRAS G12C inhibitor.

Luo’s excitement for the zoldonrasib and elisrasib readouts reflects her expectation that “there will likely be multiple approved targeted treatment options for RAS [mutant] cancers in the coming years.”

Zoldonrasib and elisrasib also reflect the ongoing use of small molecules in oncology. Companies are still using the well-established modality in exciting new ways, Allan Jordan, vice president of oncology drug discovery at Sygnature Discovery, told BioSpace via email. Jordan named intrinsically disordered proteins, transcription factors and mRNA as challenging targets that researchers are tackling with small molecules.

Drugs targeting enzyme classes such as helicases “remain a vibrant field” for small molecules, Jordan said. Amgen and Eikon Therapeutics, which raised $381 million in an IPO this year, are among the companies sharing data on helicase inhibitors at AACR 2026.

ADCs enter new era

KRAS-targeted therapies made Lillian Siu’s top areas to watch at AACR 2026, but in an email to BioSpace, the Princess Margaret Cancer Centre medical oncologist also named modalities such as antibody-drug conjugates (ADCs) among the updates she is most looking forward to. Timothy Yap, a medical oncologist at the University of Texas MD Anderson Cancer Center, also highlighted ADCs in his email to BioSpace.

The clinical trials plenary on April 19 will feature data on ADCs including CSPC Pharmaceutical’s EGFR candidate, Qilu Pharmaceutical’s claudin 6 prospect and a B7-H3-targeted asset that GSK licensed from Hansoh Pharma for $185 million upfront. Those candidates are traditional ADCs, with each featuring a targeting antibody conjugated to a cytotoxic topoisomerase I inhibitor.

AACR 2026 will also feature presentations on candidates that diverge from the standard ADC design. Astellas is presenting preclinical data on an ADC that carries two payloads to cells expressing TROP2, the receptor targeted by Gilead’s Trodelvy and AstraZeneca and Daiichi Sankyo’s Datroway. Duality Biologics, which has deals with BioNTech and GSK, is among the other companies sharing data on a dual-payload ADC.

The types of payloads are changing, too. Sygnature’s Jordan said it is interesting to finally see the ADC field move “away from traditional cytotoxic payloads toward more cancer-selective payloads which have the potential to improve tolerability and patient benefit.”

Elsewhere, multiple companies are sharing data on degrader-antibody conjugates (DACs), which deliver molecules that drive protein degradation rather than the cytotoxic payloads used in ADCs. Roche recently struck an up to $1 billion DAC deal with C4 Therapeutics, joining rivals including BMS in the emerging field.

At AACR 2026, Helioson Pharmaceutical is sharing late-breaking research on a DAC designed to degrade IKZF1/3, transcription factors needed for the growth and survival of multiple myeloma cells. CSPC, which like Helioson is based in China, is also presenting data on a DAC targeting IKZF1/3. Orum Therapeutics, a partner of BMS and Vertex, is among the other companies showcasing DAC data at the event.

The various projects illustrate the potential benefits of DACs, with CSPC using a CD38 antibody to trigger a dual mechanism of action and Orum leveraging the modality to achieve a wider therapeutic window than is possible with standard GSPT1 degraders. However, traditional degraders remain viable and the field continues to evolve, with Jordan naming the rise of glues targeting E3 ligases other than cereblon as a trend to watch.

ADCs, DACs and protein degraders are just some of the modalities that will be showcased at the event. Multispecific antibodies and novel induced proximity strategies are among the other areas Yap will be keeping an eye out for, while Siu will be watching for data on CAR T cell therapy and immunotherapy in precursor malignancies.

AACR runs from April 17 to April 22. 

https://www.biospace.com/drug-development/mercks-pd-1-vegf-data-star-in-stacked-lineup-of-aacr-26-data-reveals

Trump says Iran agreed to suspend nuclear program indefinitely – Bloomberg

 

US President Donald Trump told Bloomberg on Friday Iran had agreed to suspend its nuclear program indefinitely and will not receive any frozen funds from Washington.

He also said that a deal to end the war is “mostly complete."

https://www.iranintl.com/en/liveblog/202604159162

Trump negotiating with Iran himself, got ‘loud’ on recent call, Graham says

 

"President Trump is directly talking to the Iranians. He is negotiating himself," Republican Senator Lindsey Graham told Fox News.

"He was on the phone with the Iranians a couple of days ago, and it got rather sporty to the point that President Trump loudly told Iran what would happen if they keep playing games. He actually lost his voice," Graham, an ally of Trump, said.

"I'd hate to be the Iranian on the receiving end of that. So President Trump is now directly involved in the negotiations."

https://www.iranintl.com/en/liveblog/202604159162

State media slam Araghchi's Hormuz tweet, say it let Trump claim victory

 

Iran's state media issued rare and sharply worded criticism of Foreign Minister Abbas Araghchi and the negotiating team after he declared the reopening of Hormuz Strait on X, saying the move created confusion and gave Trump an opening to claim victory.

Araghchi's post was widely criticized by hardliners and their outlets, including the state-run Mehr News which said Araghchi's tweet "provided the best opportunity for Trump to go beyond reality, declare himself the winner of the war and celebrate victory."

"It is clear that ceasefire-related negotiations are not being handled solely by the Foreign Ministry. Therefore, it is natural that under these circumstances the entire team should collectively explain the decisions that have been made," Mehr News said.

Tasnim News Agency described the post as a “bad and incomplete tweet that created misleading ambiguity about the reopening of the Strait of Hormuz."

https://www.iranintl.com/en/liveblog/202604159162